Carlsmed Q1 revenue $16.1M (+58% YoY); raises FY2026 guidance to $72-77M

CARLSMED, INC.

2026-Q1 EPS reported -$0.32 revenue$16,116,000

Revenue $16.1M, up 58% YoY from $10.2M; gross margin 77.1% vs 74.9%.
Net loss ($8.7M) vs ($5.7M); adjusted EBITDA ($7.5M) vs ($5.5M).
FY2026 revenue guidance raised to $72-$77M from prior $70-$75M.
Study in Global Spine Journal shows 74% reduction in reoperations with aprevo implants.
First procedures completed with corra cervical plating system and aprevo bi-lateral posterior in Feb.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CARLSMED, INC. reported first quarter ended March 31, 2026 results: revenue $16.1 million, net income ($8.7) million. Guidance raised.

Period: first quarter ended March 31, 2026
Revenue: $16.1 million
Net income: ($8.7) million
Guidance: raised
Result: reported results

Exact text from the filing

set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Carlsmed ® Reports First Quarter 2026 Financial Results First quarter 2026 revenue of $16.1 million, representing 58% growth year-over-year Full year 2026 revenue guidance raised to $72 million to $77 million CARLSBAD, CALIFORNIA, MAY 5, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc.

View on SEC.gov

Browse all earnings releases →

CARLSMED, INC. filing history →

Source: SEC EDGAR

accession 0001794546-26-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.